TrivarX Limited

TRI

AU0000300196

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
0.035 ^AUD	-2.78%		+25.00%	+16.67%

07-10	TrivarX Completes Phase 2 Sleep Signal Analysis for Current Major Depressive Episode Study; Shares Surge 11%	MT
06-21	TrivarX Recruits 362 Patients for Phase-Two MEB-001 Sleep Signal Analysis Study	MT

Medibio Limited Announces Resignation of Adam Darkins from the Board of Directors

January 18, 2018 at 06:01 pm

Medibio Limited announced that Dr. Adam Darkins has resigned from the Board of Directors of Medibio due to time constraints.

Latest news about TrivarX Limited

TrivarX Completes Phase 2 Sleep Signal Analysis for Current Major Depressive Episode Study; Shares Surge 11%	07-09	MT
TrivarX Recruits 362 Patients for Phase-Two MEB-001 Sleep Signal Analysis Study	06-20	MT
TrivarX Receives Firm Commitments for AU$2.5 Million Share Issuance; Shares Jump 27%	05-01	MT
TrivarX Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
TrivarX Signs Collaboration with Northern Michigan University on Sleep Research	02-08	MT
TrivarX Secures R&D Tax Rebate for Fiscal Year 2023; Shares Fall 4%	02-07	MT
Over Half of Patients On Track for Completion in TrivarX's SAMDE Study	02-07	MT
TrivarX Undertaking 1-for-20 Securities Consolidation	23-10-18	MT
Medibio Limited has Changed its Name to TrivarX Limited	23-10-06	CI
Medibio Limited Announces Dr. Thomas Young Will Transition from His Role as Part-Time Chief Executive Officer to Non-Executive Director	23-10-05	CI
Medibio Limited Announces Dr. Thomas Young Will Transition from His Role as Part-Time Chief Executive Officer to Non-Executive Director	23-10-05	CI
Medibio Begins Phase Two Trial for Sleep Algorithm	23-09-03	MT
TrivarX Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Medibio Completes Phase One Depressive Episode Sleep Trial	23-07-24	MT
US FDA Denies Breakthrough Device Designation for Medibio’s Depression Diagnostic Device	23-07-20	MT
Medibio Completes Shares Purchase Plan	23-05-29	MT
Medibio Adds Executive Director Role to CEO, Changes Principal Pace of Business	23-04-12	MT
Medibio Limited Announces Board & Management Changes	23-04-11	CI
Medibio Limited Announces Change of Registered Office and Principal Place of Business	23-04-11	CI
Medibio Limited Announces Resignation of Matt Mesnik as Non-Executive Director	23-03-16	CI
Medibio Limited Lodges Breakthrough Device Designation with FDA	23-02-26	CI
TrivarX Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-24	CI
Medibio Limited Appoints Christopher Ntoumenopoulos as Director	23-02-16	CI
Medibio to Raise AU$2.8 Million in Placement, Share Purchase Plan	23-02-15	MT
Medibio Receives R&D Tax Rebate	22-11-14	MT

TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Companyâs corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is conducting clinical research, product development and early-stage commercialization of a mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. It has launched its consumer mobile application to help measure, monitor, and manage stress, called LUCA. LUCA is a biometric assessment tool that measures sleep stress, activity stress, and cardiac stress that allows consumers to monitor their daily stress levels through their own personal wearable device.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
TRIVARX LIMITED	+16.67%	10.96M
KYOWA KIRIN CO. LTD.	+34.09%	10.31B
YUHAN CORPORATION	+40.41%	5.23B
SK BIOPHARMACEUTICALS CO., LTD.	-15.24%	4.62B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+11.62%	3.52B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+26.25%	2.31B
BETTA PHARMACEUTICALS CO., LTD.	-38.78%	1.78B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-44.54%	1.69B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	+0.69%	1.59B

Specialty & Advanced Pharmaceuticals

TrivarX Limited

Equities

TRI

AU0000300196

Pharmaceuticals

Medibio Limited Announces Resignation of Adam Darkins from the Board of Directors

Latest news about TrivarX Limited

Chart TrivarX Limited

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals